-
1
-
-
84857042496
-
Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts
-
RABQUER BJ, KOCH AE: Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012; 14: 56-63.
-
(2012)
Curr Rheumatol Rep
, vol.14
, pp. 56-63
-
-
Rabquer, B.J.1
Koch, A.E.2
-
3
-
-
38349097387
-
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
-
CHIFFLOT H, FAUTREL B, SORDET C, CHATELUS E, SIBILIA J: Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review. Semin Arthritis Rheum 2008; 37: 223-35.
-
(2008)
Semin Arthritis Rheum
, vol.37
, pp. 223-235
-
-
Chifflot, H.1
Fautrel, B.2
Sordet, C.3
Chatelus, E.4
Sibilia, J.5
-
4
-
-
0038799783
-
Scleroderma epidemiology
-
MAYES M: Scleroderma epidemiology. Rheum Dis Clin N Am 2003; 29: 239-54.
-
(2003)
Rheum Dis Clin N Am
, vol.29
, pp. 239-254
-
-
Mayes, M.1
-
5
-
-
0023854176
-
Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis
-
LeROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
-
(1988)
J Rheumatol
, vol.15
, pp. 202-205
-
-
Leroy, E.C.1
Black, C.2
Fleischmajer, R.3
-
6
-
-
74449087538
-
Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital
-
JOVEN BE, ALMODOVAR R, CARMONA L, CARREIRA PE: Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 2010; 39: 285-93.
-
(2010)
Semin Arthritis Rheum
, vol.39
, pp. 285-293
-
-
Joven, B.E.1
Almodovar, R.2
Carmona, L.3
Carreira, P.E.4
-
7
-
-
74449085877
-
Determinants of morbidity and mortality of systemic sclerosis in Canada
-
Al-DHAHER FF, POPE JE, OUIMET JM: Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39: 269-77.
-
(2010)
Semin Arthritis Rheum
, vol.39
, pp. 269-277
-
-
Al-Dhaher, F.F.1
Pope, J.E.2
Ouimet, J.M.3
-
10
-
-
38349097387
-
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
-
CHIFFLOT H, FAUTREL B, SORDET C, CHATELUS E, SIBILIA J: Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review. Semin Arthritis Rheum 2008; 37: 223-35.
-
(2008)
Semin Arthritis Rheum
, vol.37
, pp. 223-235
-
-
Chifflot, H.1
Fautrel, B.2
Sordet, C.3
Chatelus, E.4
Sibilia, J.5
-
11
-
-
0038799783
-
Scleroderma epidemiology
-
MAYES M: Scleroderma epidemiology. Rheum Dis Clin N Am 2003; 29: 239-54.
-
(2003)
Rheum Dis Clin N Am
, vol.29
, pp. 239-254
-
-
Mayes, M.1
-
12
-
-
0023854176
-
Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis
-
LeROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
-
(1988)
J Rheumatol
, vol.15
, pp. 202-205
-
-
Leroy, E.C.1
Black, C.2
Fleischmajer, R.3
-
13
-
-
74449087538
-
Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital
-
JOVEN BE, ALMODOVAR R, CARMONA L, CARREIRA PE: Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 2010; 39: 285-93.
-
(2010)
Semin Arthritis Rheum
, vol.39
, pp. 285-293
-
-
Joven, B.E.1
Almodovar, R.2
Carmona, L.3
Carreira, P.E.4
-
14
-
-
74449085877
-
Determinants of morbidity and mortality of systemic sclerosis in Canada
-
Al-DHAHER FF, POPE JE, OUIMET JM: Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39: 269-77.
-
(2010)
Semin Arthritis Rheum
, vol.39
, pp. 269-277
-
-
Al-Dhaher, F.F.1
Pope, J.E.2
Ouimet, J.M.3
-
15
-
-
0031855190
-
Mortality and causes of death of 344 Dan ish patients with systemic sclerosis (scleroderma)
-
JACOBSEN S, HALBERG P, ULLMAN S: Mortality and causes of death of 344 Dan ish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998; 37: 750-5.
-
(1998)
Br J Rheumatol
, vol.37
, pp. 750-755
-
-
Jacobsen, S.1
Halberg, P.2
Ullman, S.3
-
16
-
-
37749017657
-
Survival and causes of death in 366 Hungarian patients with systemic sclerosis
-
CZIRJÁK L, KUMÁNOVICS G, VARJú C et al.: Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 59-63.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 59-63
-
-
Czirják, L.1
Kumánovics, G.2
Varjú, C.3
-
17
-
-
78650415467
-
Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis
-
BARAUT J, MICHEL L, VERRECCHIA F, FARGE D: Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010; 10: 65-73.
-
(2010)
Autoimmun Rev
, vol.10
, pp. 65-73
-
-
Baraut, J.1
Michel, L.2
Verrecchia, F.3
Farge, D.4
-
18
-
-
84859438199
-
The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
-
SMOLEN JS, ALETAHA D, REDLICH K: The pathogenesis of rheumatoid arthritis: new insights from old clinical data?. Nat Rev Rheumatol 2012; 8: 235-43.
-
(2012)
Nat Rev Rheumatol
, vol.8
, pp. 235-243
-
-
Smolen, J.S.1
Aletaha, D.2
Redlich, K.3
-
19
-
-
84878134773
-
Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage
-
ABDEL MEGUID MH, HAMAD YH, SWILAM RS, BARAKAT MS: Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol Int 2013; 33: 697-703.
-
(2013)
Rheumatol Int
, vol.33
, pp. 697-703
-
-
Abdel Meguid, M.H.1
Hamad, Y.H.2
Swilam, R.S.3
Barakat, M.S.4
-
20
-
-
84864481289
-
Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis
-
SAMSON M, AUDIA S, JANIKASHVILI N et al.: Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 2499-503.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 2499-2503
-
-
Samson, M.1
Audia, S.2
Janikashvili, N.3
-
21
-
-
84859624578
-
Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting theinterleukin-6 receptor
-
NAVARRO-MILLÁN I, SINGH JA, CURTIS JR: Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting theinterleukin-6 receptor. Clin Ther 2012; 34: 788-802.
-
(2012)
Clin Ther
, vol.34
, pp. 788-802
-
-
Navarro-Millán, I.1
Singh, J.A.2
Curtis, J.R.3
-
22
-
-
0042744797
-
C-reactive protein: a critical update
-
PEPYS MB, HIRSCHFIELD GM: C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.
-
(2003)
J Clin Invest
, vol.111
, pp. 1805-1812
-
-
Pepys, M.B.1
Hirschfield, G.M.2
-
23
-
-
0027159417
-
Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis
-
GABAY C, ROUX-LOMBARD P, de MOERLOOSE P, DAYER JM, VISCHER T, GUERNE PA: Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993; 20: 815-21.
-
(1993)
J Rheumatol
, vol.20
, pp. 815-821
-
-
Gabay, C.1
Roux-Lombard, P.2
de Moerloose, P.3
Dayer, J.M.4
Vischer, T.5
Guerne, P.A.6
-
24
-
-
34250166546
-
Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis
-
EMERY P, GABAY C, KRAAN M, GOMEZREINO J: Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007; 27: 793-806.
-
(2007)
Rheumatol Int
, vol.27
, pp. 793-806
-
-
Emery, P.1
Gabay, C.2
Kraan, M.3
Gomezreino, J.4
-
25
-
-
79956159584
-
Highsensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus
-
FIROOZ N, ALBERT DA, WALLACE DJ, ISHIMORI M, BEREL D, WEISMAN MH: Highsensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus 2011; 20: 588-97.
-
(2011)
Lupus
, vol.20
, pp. 588-597
-
-
Firooz, N.1
Albert, D.A.2
Wallace, D.J.3
Ishimori, M.4
Berel, D.5
Weisman, M.H.6
-
26
-
-
84861805021
-
Interleukin 6 in systemic sclerosis and potential implications for targeted therapy
-
MUANGCHAN C, POPE JE: Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol 2012; 39: 1120-4.
-
(2012)
J Rheumatol
, vol.39
, pp. 1120-1124
-
-
Muangchan, C.1
Pope, J.E.2
-
27
-
-
84865593221
-
C - reactive protein (CRP) is associated with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG)
-
MUANGCHAN C, HARDING S, KHIMDAS S, BONNER A, BARON M, POPE J; the Canadian Scleroderma Research Group (CSRG): C - reactive protein (CRP) is associated with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG). Arthritis Care Res (Hoboken) 2012; 64: 1405-14.
-
(2012)
Arthritis Care Res (Hoboken)
, vol.64
, pp. 1405-1414
-
-
Muangchan, C.1
Harding, S.2
Khimdas, S.3
Bonner, A.4
Baron, M.5
Pope, J.6
-
28
-
-
73249149749
-
Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: Evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines
-
GOURH P, AGARWAL SK, DIVECHA D et al.: Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: Evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009; 60: 3794-806.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 3794-3806
-
-
Gourh, P.1
Agarwal, S.K.2
Divecha, D.3
-
29
-
-
47249132572
-
Ability of epistatic interactions of cytokine singlenucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients
-
BERETTA L, CAPPIELLO F, MOORE JH, BARILI M, GREENE CS, SCORZA R: Ability of epistatic interactions of cytokine singlenucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients. Arthritis Care Res 2008; 59: 974-83.
-
(2008)
Arthritis Care Res
, vol.59
, pp. 974-983
-
-
Beretta, L.1
Cappiello, F.2
Moore, J.H.3
Barili, M.4
Greene, C.S.5
Scorza, R.6
-
30
-
-
84867200145
-
The IL-6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis
-
SFRENT-CORNATEANU R, MIHAI C, BALAN S, IONESCU R, MOLDOVEANU E: The IL-6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis. J Cell Mol Med 2006; 10: 955-9.
-
(2006)
J Cell Mol Med
, vol.10
, pp. 955-959
-
-
Sfrent-Cornateanu, R.1
Mihai, C.2
Balan, S.3
Ionescu, R.4
Moldoveanu, E.5
-
31
-
-
84855281875
-
A rare polymorphism in the gene for toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators
-
BROEN JCA, BOSSINI-CASTILLO L, Van BON L et al.: A rare polymorphism in the gene for toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis Rheum 2012; 64: 264-71.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 264-271
-
-
Broen, J.C.A.1
Bossini-Castillo, L.2
Van Bon, L.3
-
32
-
-
84870315000
-
Influence of the IL6 gene in susceptibility to systemic sclerosis
-
CNIT MC, SIMEóN CP, VONK MC et al.: Influence of the IL6 gene in susceptibility to systemic sclerosis. J Rheumatol 2012; 39: 2294-302.
-
(2012)
J Rheumatol
, vol.39
, pp. 2294-2302
-
-
Cénit, M.C.1
Simeón, C.P.2
Vonk, M.C.3
-
33
-
-
84864823236
-
No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and systemic sclerosis
-
CÉNIT MC, SIMEóN CP, FONOLLOSA V et al.; Spanish Scleroderma Group: No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and systemic sclerosis. Tissue Antigens 2012; 80: 254-8.
-
(2012)
Tissue Antigens
, vol.80
, pp. 254-258
-
-
Cénit, M.C.1
Simeón, C.P.2
Fonollosa, V.3
-
34
-
-
84884935041
-
Association study of CRP gene in systemic sclerosis in European Caucasian population
-
2013 Feb. 9 [Epub ahead of print]
-
WIPFF J, DIEUDÉ P, AVOUAC J et al.: Association study of CRP gene in systemic sclerosis in European Caucasian population. 2013 Feb. 9 [Epub ahead of print].
-
-
-
Wipff, J.1
Dieudé, P.2
Avouac, J.3
-
35
-
-
83455230778
-
Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma
-
KITABA S, MUROTA H, TERAO M et al.: Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012; 180: 165-76.
-
(2012)
Am J Pathol
, vol.180
, pp. 165-176
-
-
Kitaba, S.1
Murota, H.2
Terao, M.3
-
36
-
-
80155206307
-
Immunization with DNA topoisomerase 1 and freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling
-
YOSHIZAKI A, YANABA K, OGAWA A, ASANO Y, KADONO T, SATO S: Immunization with DNA topoisomerase 1 and freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011; 63: 3575-85.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 3575-3585
-
-
Yoshizaki, A.1
Yanaba, K.2
Ogawa, A.3
Asano, Y.4
Kadono, T.5
Sato, S.6
-
37
-
-
78751701215
-
Allograft inflammatory factor-1 is over expressed and induces fibroblast chemotaxis in the skin of sclerodermatous GVHD in a murine model
-
YAMAMOTO A, ASHIHARA E, NAKAGAWA Y et al.: Allograft inflammatory factor-1 is over expressed and induces fibroblast chemotaxis in the skin of sclerodermatous GVHD in a murine model. Immunol Lett 2011; 135: 144-50.
-
(2011)
Immunol Lett
, vol.135
, pp. 144-150
-
-
Yamamoto, A.1
Ashihara, E.2
Nakagawa, Y.3
-
38
-
-
84870516776
-
IL-6 blockade attenuates the development of murine sclerodermatous chronic graftversus- host disease
-
Le HUU D, MATSUSHITA T, JIN G et al.: IL-6 blockade attenuates the development of murine sclerodermatous chronic graftversus- host disease. J Invest Dermatol 2012; 132: 2752-61.
-
(2012)
J Invest Dermatol
, vol.132
, pp. 2752-2761
-
-
Le Huu, D.1
Matsushita, T.2
Jin, G.3
-
39
-
-
0032739412
-
CD19 is a central response regulator of B lymphocyte signaling thresholds governing autoimmunity
-
SATO S: CD19 is a central response regulator of B lymphocyte signaling thresholds governing autoimmunity. J Dermatol Sci 1999; 22: 1-10.
-
(1999)
J Dermatol Sci
, vol.22
, pp. 1-10
-
-
Sato, S.1
-
40
-
-
16544364829
-
The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system
-
TEDDER TF, POE JC, FUJIMOTO M, HAAS KM, SATO S: The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimmun 2005; 8: 55-90.
-
(2005)
Curr Dir Autoimmun
, vol.8
, pp. 55-90
-
-
Tedder, T.F.1
Poe, J.C.2
Fujimoto, M.3
Haas, K.M.4
Sato, S.5
-
41
-
-
78649835509
-
Targeting BAFF in autoimmunity
-
DAVIDSON A: Targeting BAFF in autoimmunity. Curr Opin Immunol 2010; 22: 732-9.
-
(2010)
Curr Opin Immunol
, vol.22
, pp. 732-739
-
-
Davidson, A.1
-
42
-
-
70349658717
-
BAFF: a local and systemic target in autoimmune diseases
-
MOISINI I, DAVIDSON A: BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 2009; 158: 155-63.
-
(2009)
Clin Exp Immunol
, vol.158
, pp. 155-163
-
-
Moisini, I.1
Davidson, A.2
-
43
-
-
34247574625
-
B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling
-
MACKAY F, SILVEIRA PA, BRINK R: B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007; 19: 327-36.
-
(2007)
Curr Opin Immunol
, vol.19
, pp. 327-336
-
-
Mackay, F.1
Silveira, P.A.2
Brink, R.3
-
44
-
-
44849130732
-
CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma
-
YOSHIZAKI A, IWATA Y, KOMURA K et al.: CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172: 1650-63.
-
(2008)
Am J Pathol
, vol.172
, pp. 1650-1663
-
-
Yoshizaki, A.1
Iwata, Y.2
Komura, K.3
-
45
-
-
0036262665
-
CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse
-
SAITO E, FUJIMOTO M, HASEGAWA M et al.: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002; 109: 1453-62.
-
(2002)
J Clin Invest
, vol.109
, pp. 1453-1462
-
-
Saito, E.1
Fujimoto, M.2
Hasegawa, M.3
-
46
-
-
36248941233
-
BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice
-
MATSUSHITA T, FUJIMOTO M, HASEGAWA M et al.: BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 2007; 127: 2772- 80.
-
(2007)
J Invest Dermatol
, vol.127
-
-
Matsushita, T.1
Fujimoto, M.2
Hasegawa, M.3
-
47
-
-
0034468138
-
Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation
-
ORTMANN RA, CHENG T, VISCONTI R, FRUCHT DM, O'SHEA JJ: Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation. Arthritis Res 2000; 2: 16-32.
-
(2000)
Arthritis Res
, vol.2
, pp. 16-32
-
-
Ortmann, R.A.1
Cheng, T.2
Visconti, R.3
Frucht, D.M.4
O'shea, J.J.5
-
48
-
-
84859972127
-
JAK and STAT signaling molecules in immunoregulation and immune-mediated disease
-
O'SHEA JJ, PLENGE R: JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012; 36: 542-50.
-
(2012)
Immunity
, vol.36
, pp. 542-550
-
-
O'sHea, J.J.1
Plenge, R.2
-
50
-
-
84555205600
-
IL-6/IL-6 receptor system and its role in physiological and pathological conditions
-
MIHARA M, HASHIZUME M, YOSHIDA H, SUZUKI M, SHIINA M: IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012; 122: 143-59.
-
(2012)
Clin Sci (Lond)
, vol.122
, pp. 143-159
-
-
Mihara, M.1
Hashizume, M.2
Yoshida, H.3
Suzuki, M.4
Shiina, M.5
-
51
-
-
79953676584
-
Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis
-
AVOUAC J, FüRNROHR BG, TOMCIK M et al.: Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011; 63: 800-9.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 800-809
-
-
Avouac, J.1
Fürnrohr, B.G.2
Tomcik, M.3
-
53
-
-
77952943759
-
Inducible co stimulator ligand regulates bleomycin- induced lung and skin fibrosis in a mouse model independently of the inducible co stimulator/inducible co stimulator ligand pathway
-
TANAKA C, FUJIMOTO M, HAMAGUCHI Y, SATO S, TAKEHARA K, HASEGAWA M: Inducible co stimulator ligand regulates bleomycin- induced lung and skin fibrosis in a mouse model independently of the inducible co stimulator/inducible co stimulator ligand pathway. Arthritis Rheum 2010; 62: 1723- 32.
-
(2010)
Arthritis Rheum
, vol.62
-
-
Tanaka, C.1
Fujimoto, M.2
Hamaguchi, Y.3
Sato, S.4
Takehara, K.5
Hasegawa, M.6
-
54
-
-
80053495041
-
The specific free radical scavenger edaravone suppresses fibrosis in the bleomycininduced and tight skin mouse models of systemic sclerosis
-
YOSHIZAKI A, YANABA K, OGAWA A et al.: The specific free radical scavenger edaravone suppresses fibrosis in the bleomycininduced and tight skin mouse models of systemic sclerosis. Arthritis Rheum 2011; 63: 3086-97.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 3086-3097
-
-
Yoshizaki, A.1
Yanaba, K.2
Ogawa, A.3
-
55
-
-
77955349716
-
Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis
-
YOSHIZAKI A, YANABA K, YOSHIZAKI A et al.: Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010; 62: 2476-87.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 2476-2487
-
-
Yoshizaki, A.1
Yanaba, K.2
Yoshizaki, A.3
-
56
-
-
73249139173
-
Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized single-blind pilot study
-
SU TI, KHANNA D, FURST DE et al.: Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized single-blind pilot study. Arthritis Rheum 2009; 60: 3821-30.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 3821-3830
-
-
Su, T.I.1
Khanna, D.2
Furst, D.E.3
-
57
-
-
77955708579
-
Inhibition of bleomycin-induced pulmonary fibrosis through pre-treatment with collagen type V
-
BRAUN RK, MARTIN A, SHAH S et al.: Inhibition of bleomycin-induced pulmonary fibrosis through pre-treatment with collagen type V. J Heart Lung Transplant 2010; 29: 873-80.
-
(2010)
J Heart Lung Transplant
, vol.29
, pp. 873-880
-
-
Braun, R.K.1
Martin, A.2
Shah, S.3
-
58
-
-
45349109299
-
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in latephase disease
-
POSTLETHWAITE AE, WONG WK, CLEMENTS P et al.: A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in latephase disease. Arthritis Rheum 2008; 58: 1810-22.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 1810-1822
-
-
Postlethwaite, A.E.1
Wong, W.K.2
Clements, P.3
-
59
-
-
0033017344
-
Anti-sclerotic effect of transforming growth factor-ß antibody in a mouse model of bleomycin-induced scleroderma
-
YAMAMOTO T, TAKAGAWA S, KATAYAMA I, NISHIOKA K: Anti-sclerotic effect of transforming growth factor-ß antibody in a mouse model of bleomycin-induced scleroderma. Clinical Immunology 1999; 92: 6-13.
-
(1999)
Clinical Immunology
, vol.92
, pp. 6-13
-
-
Yamamoto, T.1
Takagawa, S.2
Katayama, I.3
Nishioka, K.4
-
60
-
-
33846250366
-
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT- 192
-
DENTON CP, MERKEL PA, FURST DE et al.: Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT- 192. Arthritis Rheum 2007; 56: 323-33.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 323-333
-
-
Denton, C.P.1
Merkel, P.A.2
Furst, D.E.3
-
61
-
-
84860734406
-
Systemic sclerosis fibroblasts show specific alterations of interferon-? and tumor necrosis factor-a-induced modulation of interleukin 6 and chemokine ligand 2
-
ANTONELLI A, FALLAHI P, FERRARI SM et al.: Systemic sclerosis fibroblasts show specific alterations of interferon-? and tumor necrosis factor-a-induced modulation of interleukin 6 and chemokine ligand 2. J Rheumatol 2012; 39: 979-85.
-
(2012)
J Rheumatol
, vol.39
, pp. 979-985
-
-
Antonelli, A.1
Fallahi, P.2
Ferrari, S.M.3
-
62
-
-
84862520877
-
Clinical and pathological significance of interleukin 6 over expression in systemic sclerosis
-
KHAN K, XU S, NIHTYANOVA S et al.: Clinical and pathological significance of interleukin 6 over expression in systemic sclerosis. Ann Rheum Dis 2012; 71: 1235-42.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 1235-1242
-
-
Khan, K.1
Xu, S.2
Nihtyanova, S.3
-
63
-
-
83455210338
-
IFN-γ and TNF-a induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls
-
ANTONELLI A, FERRI C, FERRARI SM et al.: IFN-γ and TNF-a induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls. Scand J Rheumatol 2011; 40: 453-6.
-
(2011)
Scand J Rheumatol
, vol.40
, pp. 453-456
-
-
Antonelli, A.1
Ferri, C.2
Ferrari, S.M.3
-
64
-
-
77954222254
-
Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: Is T-cell response aimed to play a protective role?
-
De PALMA R, D'AIUTO E, VETTORI S, CUOPPOLO P, ABBATE G, VALENTINI G: Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: Is T-cell response aimed to play a protective role?. Rheumatology 2010; 49: 1257-66.
-
(2010)
Rheumatology
, vol.49
, pp. 1257-1266
-
-
De Palma, R.1
D'aiuto, E.2
Vettori, S.3
Cuoppolo, P.4
Abbate, G.5
Valentini, G.6
-
65
-
-
70349785531
-
Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts
-
GARCIA-GONZALEZ E, SELVI E, BALISTRERI E et al.: Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology 2009; 48: 1050-6.
-
(2009)
Rheumatology
, vol.48
, pp. 1050-1056
-
-
Garcia-Gonzalez, E.1
Selvi, E.2
Balistreri, E.3
-
66
-
-
0031935542
-
Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts
-
KADONO T, KIKUCHI K, IHN H, TAKEHARA K, TAMAKI K: Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998; 25: 296-301.
-
(1998)
J Rheumatol
, vol.25
, pp. 296-301
-
-
Kadono, T.1
Kikuchi, K.2
Ihn, H.3
Takehara, K.4
Tamaki, K.5
-
67
-
-
0026767273
-
Mechanisms of pathogenesis in scleroderma. I. overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma
-
FEGHALI CA, BOST KL, BOULWARE DW, LEVY LS: Mechanisms of pathogenesis in scleroderma. I. overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992; 19: 1207-11.
-
(1992)
J Rheumatol
, vol.19
, pp. 1207-1211
-
-
Feghali, C.A.1
Bost, K.L.2
Boulware, D.W.3
Levy, L.S.4
-
68
-
-
0032011592
-
Spontaneous cytokine gene expression by cultured skin fibroblasts of systemic sclerosis. correlation with collagen synthesis
-
ZURITA-SALINAS CS, RICHAUD-PATIN Y, KRöTZSCH-GóMEZ E et al.: Spontaneous cytokine gene expression by cultured skin fibroblasts of systemic sclerosis. correlation with collagen synthesis. Revista de Investigacion Clinica 1998; 50: 97-104.
-
(1998)
Revista de Investigacion Clinica
, vol.50
, pp. 97-104
-
-
Zurita-Salinas, C.S.1
Richaud-Patin, Y.2
Krötzsch-Gómez, E.3
-
69
-
-
0027933282
-
Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis
-
FEGHALI CA, BOST KL, BOULWARE DW, LEVY LS: Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. Autoimmunity 1994; 17: 309-18.
-
(1994)
Autoimmunity
, vol.17
, pp. 309-318
-
-
Feghali, C.A.1
Bost, K.L.2
Boulware, D.W.3
Levy, L.S.4
-
71
-
-
0035925040
-
Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts
-
KONDO K, OKADA T, MATSUI T et al.: Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts. Cytokine 2001; 13: 220-6.
-
(2001)
Cytokine
, vol.13
, pp. 220-226
-
-
Kondo, K.1
Okada, T.2
Matsui, T.3
-
72
-
-
33749243490
-
Intracellular IL-1a-binding proteins contribute to biological functions of endogenous IL-1a in systemic sclerosis fibroblasts
-
KAWAGUCHI Y, NISHIMAGI E, TOCHIMOTO A et al.: Intracellular IL-1a-binding proteins contribute to biological functions of endogenous IL-1a in systemic sclerosis fibroblasts. Proc Natl Acad Sci USA 2006; 103: 14501-6.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 14501-14506
-
-
Kawaguchi, Y.1
Nishimagi, E.2
Tochimoto, A.3
-
73
-
-
5044232255
-
Autocrine activation by interleukin 1a induces the fibrogenic phenotype of systemic sclerosis fibroblasts
-
KAWAGUCHI Y, McCARTHY SA, WATKINS SC, WRIGHT TM: Autocrine activation by interleukin 1a induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 2004; 31: 1946-54.
-
(2004)
J Rheumatol
, vol.31
, pp. 1946-1954
-
-
Kawaguchi, Y.1
Mccarthy, S.A.2
Watkins, S.C.3
Wright, T.M.4
-
74
-
-
0036269002
-
Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis
-
CHIZZOLINI C, RASCHI E, REZZONICO R et al.: Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002; 46: 1602-13.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 1602-1613
-
-
Chizzolini, C.1
Raschi, E.2
Rezzonico, R.3
-
75
-
-
0033121274
-
Endogenous IL-1a from systemic sclerosis fibroblasts induces IL-6 and PDGF-A
-
KAWAGUCHI Y, HARA M, WRIGHT TM: Endogenous IL-1a from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103: 1253-60.
-
(1999)
J Clin Invest
, vol.103
, pp. 1253-1260
-
-
Kawaguchi, Y.1
Hara, M.2
Wright, T.M.3
-
76
-
-
0027280170
-
Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1ß
-
KAWAGUCHI Y, HARIGAI M, SUZUKI K et al.: Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1ß. Biochem Biophys Res Commun 1993; 190: 154-61.
-
(1993)
Biochem Biophys Res Commun
, vol.190
, pp. 154-161
-
-
Kawaguchi, Y.1
Harigai, M.2
Suzuki, K.3
-
77
-
-
0031880752
-
Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor
-
TAKEMURA H, SUZUKI H, FUJISAWA H et al.: Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor. J Rheumatol 1998; 25: 1534-9.
-
(1998)
J Rheumatol
, vol.25
, pp. 1534-1539
-
-
Takemura, H.1
Suzuki, H.2
Fujisawa, H.3
-
78
-
-
78651068822
-
Toll-like receptor 3 up regulation by type I interferon in healthy and scleroderma dermal fibroblasts
-
AGARWAL SK, WU M, LIVINGSTON CK et al.: Toll-like receptor 3 up regulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res Ther 2011; 13: R3.
-
(2011)
Arthritis Res Ther
, vol.13
-
-
Agarwal, S.K.1
Wu, M.2
Livingston, C.K.3
-
79
-
-
0033020912
-
Fibroblast proliferation by bleomycin stimulated peripheral blood mononuclear cell factors
-
YAMAMOTO T, KATAYAMA I, NISHIOKA K: Fibroblast proliferation by bleomycin stimulated peripheral blood mononuclear cell factors. J Rheumatol 1999; 26: 609-15.
-
(1999)
J Rheumatol
, vol.26
, pp. 609-615
-
-
Yamamoto, T.1
Katayama, I.2
Nishioka, K.3
-
80
-
-
45949089317
-
Pivotal advance: Th-1 cytokines inhibit, and th-2 cytokines promote fibrocyte differentiation
-
SHAO DD, SURESH R, VAKIL V, GOMER RH, PILLING D: Pivotal advance: Th-1 cytokines inhibit, and th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008; 83: 1323-33.
-
(2008)
J Leukoc Biol
, vol.83
, pp. 1323-1333
-
-
Shao, D.D.1
Suresh, R.2
Vakil, V.3
Gomer, R.H.4
Pilling, D.5
-
81
-
-
33746896971
-
Costimulation blockade and its possible future use in clinical transplantation
-
SNANOUDJ R, de PRÉNEUF H, CRÉPUT C et al.: Costimulation blockade and its possible future use in clinical transplantation. Transpl Int 2006; 19: 693-704.
-
(2006)
Transpl Int
, vol.19
, pp. 693-704
-
-
Snanoudj, R.1
De Préneuf, H.2
Créput, C.3
-
82
-
-
55849109623
-
A CD40-CD154 interaction in tissue fibrosis
-
KAWAI M, MASUDA A, KUWANA M: A CD40-CD154 interaction in tissue fibrosis. Arthritis Rheum 2008; 58: 3562-73.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 3562-3573
-
-
Kawai, M.1
Masuda, A.2
Kuwana, M.3
-
83
-
-
0242271835
-
Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): Role of CD40-CD154 in the phenotype of SSc fibroblasts
-
FUKASAWA C, KAWAGUCHI Y, HARIGAI M et al.: Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): Role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003; 33: 2792-800.
-
(2003)
Eur J Immunol
, vol.33
, pp. 2792-2800
-
-
Fukasawa, C.1
Kawaguchi, Y.2
Harigai, M.3
-
84
-
-
0029930901
-
IL- 6-soluble IL-6 receptor complex inhibits the proliferation of dermal fibroblasts
-
MIHARA M, MORIYA Y, OHSUGI Y: IL- 6-soluble IL-6 receptor complex inhibits the proliferation of dermal fibroblasts. Int J Immunopharmacol 1996; 18: 89-94.
-
(1996)
Int J Immunopharmacol
, vol.18
, pp. 89-94
-
-
Mihara, M.1
Moriya, Y.2
Ohsugi, Y.3
-
85
-
-
84869741998
-
Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts
-
STEINMAN RA, ROBINSON AR, FEGHALIBOSTWICK CA: Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts. PLoS One 2012; 7: e48560.
-
(2012)
PLoS One
, vol.7
-
-
Steinman, R.A.1
Robinson, A.R.2
Feghalibostwick, C.A.3
-
86
-
-
9644258488
-
Cytokine and chemokine levels in systemic sclerosis: Relationship with cutaneous and internal organ involvement
-
SCALA E, PALLOTTA S, FREZZOLINI A et al.: Cytokine and chemokine levels in systemic sclerosis: Relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004; 138: 540-6.
-
(2004)
Clin Exp Immunol
, vol.138
, pp. 540-546
-
-
Scala, E.1
Pallotta, S.2
Frezzolini, A.3
-
87
-
-
0032746822
-
Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis
-
HASEGAWA M, SATO S, IHN H, TAKEHARA K: Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology 1999; 38: 612-7.
-
(1999)
Rheumatology
, vol.38
, pp. 612-617
-
-
Hasegawa, M.1
Sato, S.2
Ihn, H.3
Takehara, K.4
-
88
-
-
0029913252
-
Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor ß1
-
GIACOMELLI R, CIPRIANI P, DANESE C et al.: Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor ß1. J Rheumatol 1996; 23: 294-6.
-
(1996)
J Rheumatol
, vol.23
, pp. 294-296
-
-
Giacomelli, R.1
Cipriani, P.2
Danese, C.3
-
89
-
-
0028596014
-
Augmented interleukin-6 secretion in collagenstimulated peripheral blood mononuclear cells from patients with systemic sclerosis
-
GURRAM M, PAHWA S, FRIERI M: Augmented interleukin-6 secretion in collagenstimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy 1994; 73: 493-6.
-
(1994)
Ann Allergy
, vol.73
, pp. 493-496
-
-
Gurram, M.1
Pahwa, S.2
Frieri, M.3
-
90
-
-
0032869964
-
Investigation of the alveolar macrophages and T lymphocytes in 15 patients with systemic sclerosis
-
CZIRJÁK L, KONCZ A, VARGA I, DÉVÉNYI K, KUMÁNOVICS G, SZüCS G: Investigation of the alveolar macrophages and T lymphocytes in 15 patients with systemic sclerosis. Clin Rheumatol 1999; 18: 357-63.
-
(1999)
Clin Rheumatol
, vol.18
, pp. 357-363
-
-
Czirják, L.1
Koncz, A.2
Varga, I.3
Dévényi, K.4
Kumánovics, G.5
Szücs, G.6
-
91
-
-
84873832733
-
Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts
-
HüGLE T, O'REILLY S, SIMPSON R et al.: Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthritis Rheum 2013; 65: 481-91.
-
(2013)
Arthritis Rheum
, vol.65
, pp. 481-491
-
-
Hügle, T.1
O'reilly, S.2
Simpson, R.3
-
92
-
-
0028347997
-
Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement
-
CRESTANI B, SETA N, De BANDT M et al.: Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. Am J Respir Crit Care Med 1994; 149: 1260-5.
-
(1994)
Am J Respir Crit Care Med
, vol.149
, pp. 1260-1265
-
-
Crestani, B.1
Seta, N.2
De Bandt, M.3
-
93
-
-
27744604032
-
Abnormal natural killer cell function in systemic sclerosis: Altered cytokine production and defective killing activity
-
HORIKAWA M, HASEGAWA M, KOMURA K et al.: Abnormal natural killer cell function in systemic sclerosis: Altered cytokine production and defective killing activity. J Invest Dermatol 2005; 125: 731-7.
-
(2005)
J Invest Dermatol
, vol.125
, pp. 731-737
-
-
Horikawa, M.1
Hasegawa, M.2
Komura, K.3
-
94
-
-
79961103319
-
Cytokine mRNA profile of alveolar T lymphocytes and macrophages in patients with systemic sclerosis suggests a local Tr1 response
-
ANDERSEN GN, NILSSON K, NAGAEVA O, RANTAPáá-DAHLQVIST S, SANDSTRöM T, MINCHEVA-NILSSON L: Cytokine mRNA profile of alveolar T lymphocytes and macrophages in patients with systemic sclerosis suggests a local Tr1 response. Scand J Immunol 2011; 74: 272-81.
-
(2011)
Scand J Immunol
, vol.74
, pp. 272-281
-
-
Andersen, G.N.1
Nilsson, K.2
Nagaeva, O.3
Rantapáá-Dahlqvist, S.4
Sandström, T.5
Mincheva-Nilsson, L.6
-
95
-
-
77955452418
-
Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis
-
Van BON L, POPA C, HUIJBENS R et al.: Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2010; 69: 1539-47.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1539-1547
-
-
Van Bon, L.1
Popa, C.2
Huijbens, R.3
-
96
-
-
38449105044
-
Nerve growth factor promotes TLR4 signaling-induced maturation of human dendritic cells in vitro through inducible p75NTR
-
JIANG Y, CHEN G, ZHANG Y, LU L, LIU S, CAO X: Nerve growth factor promotes TLR4 signaling-induced maturation of human dendritic cells in vitro through inducible p75NTR. Journal of Immunology 2007; 179: 6297-304.
-
(2007)
Journal of Immunology
, vol.179
, pp. 6297-6304
-
-
Jiang, Y.1
Chen, G.2
Zhang, Y.3
Lu, L.4
Liu, S.5
Cao, X.6
-
97
-
-
78751704435
-
Endothelial activation and apoptosis mediated by neutrophil- dependent interleukin 6 trans-signaling: A novel target for systemic sclerosis?
-
BARNES TC, SPILLER DG, ANDERSON ME, EDWARDS SW, MOOTS RJ: Endothelial activation and apoptosis mediated by neutrophil- dependent interleukin 6 trans-signaling: A novel target for systemic sclerosis?. Ann Rheum Dis 2011; 70: 366-72.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 366-372
-
-
Barnes, T.C.1
Spiller, D.G.2
Anderson, M.E.3
Edwards, S.W.4
Moots, R.J.5
-
98
-
-
36048960425
-
The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells
-
ROBITAILLE G, HÉNAULT J, CHRISTIN M-, SENÉCAL J-, RAYMOND Y: The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells. Arthritis Rheum 2007; 56: 3814-26.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 3814-3826
-
-
Robitaille, G.1
Hénault, J.2
Christin, M.3
Senécal, J.4
Raymond, Y.5
-
99
-
-
0034659754
-
Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells
-
KUWANA M, MEDSGER TA Jr, WRIGHT TM: Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells. J Immunol 2000; 164: 6138-46.
-
(2000)
J Immunol
, vol.164
, pp. 6138-6146
-
-
Kuwana, M.1
Medsger Jr., T.A.2
Wright, T.M.3
-
100
-
-
0026536879
-
Enhanced expression of high-affinity interleukin-2 receptors in scleroderma: Possible role for IL-6
-
KAHALEH MB, YIN T: Enhanced expression of high-affinity interleukin-2 receptors in scleroderma: Possible role for IL-6. Clin Immunol Immunopathol 1992; 62: 97-102.
-
(1992)
Clin Immunol Immunopathol
, vol.62
, pp. 97-102
-
-
Kahaleh, M.B.1
Yin, T.2
-
101
-
-
35348902738
-
T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro
-
Del GALDO F, JIMÉNEZ SA: T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro. Arthritis Rheum 2007; 56: 3478-88.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 3478-3488
-
-
Del Galdo, F.1
Jiménez, S.A.2
-
102
-
-
0033673989
-
Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis
-
SATO S, HANAKAWA H, HASEGAWA M et al.: Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 2000; 27: 2838-42.
-
(2000)
J Rheumatol
, vol.27
, pp. 2838-2842
-
-
Sato, S.1
Hanakawa, H.2
Hasegawa, M.3
-
103
-
-
31044440282
-
Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes
-
MATSUSHITA T, HASEGAWA M, YANABA K, KODERA M, TAKEHARA K, SATO S: Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006; 54: 192-201.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 192-201
-
-
Matsushita, T.1
Hasegawa, M.2
Yanaba, K.3
Kodera, M.4
Takehara, K.5
Sato, S.6
-
104
-
-
83255164768
-
Functional disturbance of the stress-adaptation system in patients with scleroderma
-
MATSUURA E, OHTA A, SUEMATSU R et al.: Functional disturbance of the stress-adaptation system in patients with scleroderma. Modern Rheumatology 2011; 21: 397-405.
-
(2011)
Modern Rheumatology
, vol.21
, pp. 397-405
-
-
Matsuura, E.1
Ohta, A.2
Suematsu, R.3
-
105
-
-
67650114978
-
The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes
-
RADSTAKE TR, van BON L, BROEN J et al.: The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes.PLoS One 2009; 4: e5903.
-
(2009)
PLoS One
, vol.4
-
-
Radstake, T.R.1
Van Bon, L.2
Broen, J.3
-
106
-
-
32144454167
-
Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: Association of interleukin 12 elevation with spontaneous regression of skin sclerosis
-
MATSUSHITA T, HASEGAWA M, HAMAGUCHI Y, TAKEHARA K, SATO S: Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: Association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006; 33: 275-84.
-
(2006)
J Rheumatol
, vol.33
, pp. 275-284
-
-
Matsushita, T.1
Hasegawa, M.2
Hamaguchi, Y.3
Takehara, K.4
Sato, S.5
-
107
-
-
6544229063
-
Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin- 6 serum changes after 12 months of therapy
-
FILACI G, CUTOLO M, SCUDELETTI M et al.: Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin- 6 serum changes after 12 months of therapy. Rheumatology 1999; 38: 992-6.
-
(1999)
Rheumatology
, vol.38
, pp. 992-996
-
-
Filaci, G.1
Cutolo, M.2
Scudeletti, M.3
-
108
-
-
0029298282
-
Serum interleukin-6 level in patients with systemic sclerosis: lack of correlation with aminoterminal propeptide of type III procollagen
-
KUCHARZ EJ, JONDERKO G, RUBISZBRZEZINSKA J, BRZEZINSKA-WCISLO L: Serum interleukin-6 level in patients with systemic sclerosis: lack of correlation with aminoterminal propeptide of type III procollagen. Clin Rheumatol 1995; 14: 380-1.
-
(1995)
Clin Rheumatol
, vol.14
, pp. 380-381
-
-
Kucharz, E.J.1
Jonderko, G.2
Rubiszbrzezinska, J.3
Brzezinska-Wcislo, L.4
-
109
-
-
75649105070
-
Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations
-
GOURH P, ARNETT FC, ASSASSI S et al.: Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009; 11: R147.
-
(2009)
Arthritis Res Ther
, vol.11
-
-
Gourh, P.1
Arnett, F.C.2
Assassi, S.3
-
110
-
-
73249114944
-
Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis
-
BEIRNE P, PANTELIDIS P, CHARLES P et al.: Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J 2009; 34: 1376-82.
-
(2009)
Eur Respir J
, vol.34
, pp. 1376-1382
-
-
Beirne, P.1
Pantelidis, P.2
Charles, P.3
-
111
-
-
0031911610
-
Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis
-
HASEGAWA M, SATO S, FUJIMOTO M, IHN H, KIKUCHI K, TAKEHARA K: Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998; 25: 308-13.
-
(1998)
J Rheumatol
, vol.25
, pp. 308-313
-
-
Hasegawa, M.1
Sato, S.2
Fujimoto, M.3
Ihn, H.4
Kikuchi, K.5
Takehara, K.6
-
112
-
-
79955802032
-
An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis
-
CODULLO V, BALDWIN HM, SINGH MD et al.: An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann Rheum Dis 2011; 70: 1115-21.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1115-1121
-
-
Codullo, V.1
Baldwin, H.M.2
Singh, M.D.3
-
113
-
-
76749145570
-
Exercise in systemic sclerosis intensifies systemic inflammation and oxidative stress
-
HARDARDóTTIR H, Van HELVOORT HAC, VONK MC, Van Den HOOGEN FHJ, DEKHUIJZEN PNR, HEIJDRA YF: Exercise in systemic sclerosis intensifies systemic inflammation and oxidative stress. Scand J Rheumatol 2010; 39: 63-70.
-
(2010)
Scand J Rheumatol
, vol.39
, pp. 63-70
-
-
Hardardóttir, H.1
Van Helvoort, H.A.C.2
Vonk, M.C.3
Van Den Hoogen, F.H.J.4
Dekhuijzen, P.N.R.5
Heijdra, Y.F.6
-
114
-
-
34047268711
-
Collagen degradation products and proinflammatory cytokines in systemic and localized scleroderma
-
BECVÁr R, HULEJOVÁ H, BRAUN M, ŠTORK J: Collagen degradation products and proinflammatory cytokines in systemic and localized scleroderma. Folia Biol 2007; 53: 66-8.
-
(2007)
Folia Biol
, vol.53
, pp. 66-68
-
-
Becvár, R.1
Hulejová, H.2
Braun, M.3
Štork, J.4
-
115
-
-
56349089937
-
The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function
-
CYPIENE A, LAUCEVICIUS A, VENALIS A et al.: The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin Rheumatol 2008; 27: 1517-22.
-
(2008)
Clin Rheumatol
, vol.27
, pp. 1517-1522
-
-
Cypiene, A.1
Laucevicius, A.2
Venalis, A.3
-
116
-
-
43749097225
-
Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors
-
HETTEMA ME, ZHANG D, de LEEUW K et al.: Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res Ther 2008; 10:R49.
-
(2008)
Arthritis Res Ther
, vol.10
-
-
Hettema, M.E.1
Zhang, D.2
de Leeuw, K.3
-
117
-
-
81555215666
-
Skin autofluorescence, as marker of accumulation of advanced glycation end products and of cumulative metabolic stress, is not increased in patients with systemic sclerosis
-
HETTEMA ME, BOOTSMA H, GRAAFF R, de VRIES R, KALLENBERG CG, SMIT AJ: Skin autofluorescence, as marker of accumulation of advanced glycation end products and of cumulative metabolic stress, is not increased in patients with systemic sclerosis. Int J Rheumatol 2011; 2011: 417-813.
-
(2011)
Int J Rheumatol
, vol.2011
, pp. 417-813
-
-
Hettema, M.E.1
Bootsma, H.2
Graaff, R.3
De Vries, R.4
Kallenberg, C.G.5
Smit, A.J.6
-
118
-
-
33748576596
-
Evaluation of cardiac laboratory markers in patients with systemic sclerosis
-
MONTAGNANA M, LIPPI G, VOLPE A et al.: Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 2006; 39: 913-7.
-
(2006)
Clin Biochem
, vol.39
, pp. 913-917
-
-
Montagnana, M.1
Lippi, G.2
Volpe, A.3
-
119
-
-
0027426209
-
Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon
-
BLANN AD, ILLINGWORTH K, JAYSON MIV: Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993; 20: 1325-30.
-
(1993)
J Rheumatol
, vol.20
, pp. 1325-1330
-
-
Blann, A.D.1
Illingworth, K.2
Jayson, M.I.V.3
-
120
-
-
52649117122
-
Increased serum fractalkine in systematic sclerosis. down-regulation by prostaglandin E1
-
SICINSKA J, GORSKA E, CICHA M et al.: Increased serum fractalkine in systematic sclerosis. down-regulation by prostaglandin E1. Clin Exp Rheumatol 2008; 26: 527-33.
-
(2008)
Clin Exp Rheumatol
, vol.26
, pp. 527-533
-
-
Sicinska, J.1
Gorska, E.2
Cicha, M.3
-
121
-
-
33746791907
-
Clinical associations of C-reactive protein in systemic sclerosis
-
ALEKPEROV RT, BARANOV AA, ABAITOVA NE: Clinical associations of C-reactive protein in systemic sclerosis. Ter Arkh 2006; 78: 30-5.
-
(2006)
Ter Arkh
, vol.78
, pp. 30-35
-
-
Alekperov, R.T.1
Baranov, A.A.2
Abaitova, N.E.3
-
122
-
-
31044448693
-
Lipoprotein[a] and the lipid profile in patients with systemic sclerosis
-
LIPPI G, CARAMASCHI P, MONTAGNANA M, SALVAGNO GL, VOLPE A, GUIDI G: Lipoprotein[a] and the lipid profile in patients with systemic sclerosis. Clinica Chimica Acta 2006; 364: 345-8.
-
(2006)
Clinica Chimica Acta
, vol.364
, pp. 345-348
-
-
Lippi, G.1
Caramaschi, P.2
Montagnana, M.3
Salvagno, G.L.4
Volpe, A.5
Guidi, G.6
-
123
-
-
84881361943
-
C-reactive protein predictsthe long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis
-
February 11 [Epub ahead of print]
-
LIU X, MAYES MD, PHD CP et al.: C-reactive protein predictsthe long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis. Arthritis Care Res (Hoboken) February 11, 2013 [Epub ahead of print].
-
(2013)
Arthritis Care Res (Hoboken)
-
-
Liu, X.1
Mayes, M.D.2
Phd, C.P.3
-
124
-
-
84877910237
-
Carbohydrate-deficient transferrin depends on disease activity in rheumatoid arthritis and systemic sclerosis
-
February 5, [Epub ahead of print]
-
GRUSZEWSKA E, CHLU.DZINSKA A, CHROSTEK L et al.: Carbohydrate-deficient transferrin depends on disease activity in rheumatoid arthritis and systemic sclerosis. Scand J Rheumatol February 5, 2013 [Epub ahead of print].
-
(2013)
Scand J Rheumatol
-
-
Gruszewska, E.1
Chlu Dzinska, A.2
Chrostek, L.3
-
125
-
-
0035465473
-
Interleukin- 2 and interleukin-6 in serum as markers of disease progression in systemic sclerosis
-
LIS AD, BRZEZINSKA-WCISLO LA: Interleukin- 2 and interleukin-6 in serum as markers of disease progression in systemic sclerosis. Pol Merkur Lekarski 2001; 11: 206-9.
-
(2001)
Pol Merkur Lekarski
, vol.11
, pp. 206-209
-
-
Lis, A.D.1
Brzezinska-Wcislo, L.A.2
-
126
-
-
0028949892
-
Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders
-
STUART RA, LITTLEWOOD AJ, MADDISON PJ, HALL ND: Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995; 13: 17-22.
-
(1995)
Clin Exp Rheumatol
, vol.13
, pp. 17-22
-
-
Stuart, R.A.1
Littlewood, A.J.2
Maddison, P.J.3
Hall, N.D.4
-
127
-
-
0032106005
-
The interleukin-1, interleukin-2, interleukin-6 and tumors necrosis factor alpha serological levels in localized and systemic sclerosis
-
ALECU M, GELERIU L, COMAN G, GALATESCU L: The interleukin-1, interleukin-2, interleukin-6 and tumors necrosis factor alpha serological levels in localized and systemic sclerosis. Rom J Intern Med 1998; 36: 251-9.
-
(1998)
Rom J Intern Med
, vol.36
, pp. 251-259
-
-
Alecu, M.1
Geleriu, L.2
Coman, G.3
Galatescu, L.4
-
128
-
-
0029670244
-
Serum cytokine and anti-Fc?R autoantibody measurements in patients with systemic sclerosis
-
SZEGEDI A, CZIRJÁK L, UNKELESS JC, BOROS P: Serum cytokine and anti-Fc?R autoantibody measurements in patients with systemic sclerosis. Acta Derm Venereol 1996; 76: 21-3.
-
(1996)
Acta Derm Venereol
, vol.76
, pp. 21-23
-
-
Szegedi, A.1
Czirják, L.2
Unkeless, J.C.3
Boros, P.4
-
129
-
-
18644363395
-
Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis
-
NAGY Z, CZIRJÁK L: Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol 2005; 23: 165-72.
-
(2005)
Clin Exp Rheumatol
, vol.23
, pp. 165-172
-
-
Nagy, Z.1
Czirják, L.2
-
130
-
-
13244272290
-
Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1ß, and tumour necrosis factor a in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis
-
HUSSEIN MR, HASSAN HI, HOFNY ERM et al.: Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1ß, and tumour necrosis factor a in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005; 58: 178-84.
-
(2005)
J Clin Pathol
, vol.58
, pp. 178-184
-
-
Hussein, M.R.1
Hassan, H.I.2
Hofny, E.R.M.3
-
131
-
-
77956203111
-
Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis
-
OHTSUKA T: Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis. J Dermatol 2010; 37: 801-6.
-
(2010)
J Dermatol
, vol.37
, pp. 801-806
-
-
Ohtsuka, T.1
-
132
-
-
42449121505
-
Platelet activation in patients with systemic scleroderma - pattern and significance
-
AGACHE I, RADOI M, DUCA L: Platelet activation in patients with systemic scleroderma - pattern and significance. Rom J Intern Med 2007; 45: 183-91.
-
(2007)
Rom J Intern Med
, vol.45
, pp. 183-191
-
-
Agache, I.1
Radoi, M.2
Duca, L.3
-
133
-
-
38949172371
-
Relation between elevated high-sensitivity C-reactive protein and antimitochondria antibody in patients with systemic sclerosis
-
OHTSUKA T: Relation between elevated high-sensitivity C-reactive protein and antimitochondria antibody in patients with systemic sclerosis. J Dermatol 2008; 35: 70-5.
-
(2008)
J Dermatol
, vol.35
, pp. 70-75
-
-
Ohtsuka, T.1
-
134
-
-
79954450466
-
Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis
-
HASEGAWA M, FUJIMOTO M, MATSUSHITA T, HAMAGUCHI Y, TAKEHARA K, SATO S: Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011; 30: 231-7.
-
(2011)
Clin Rheumatol
, vol.30
, pp. 231-237
-
-
Hasegawa, M.1
Fujimoto, M.2
Matsushita, T.3
Hamaguchi, Y.4
Takehara, K.5
Sato, S.6
-
135
-
-
25444471513
-
Clinical correlations of potential activity markers in systemic sclerosis
-
BECVÁR R, STORK J, PESÁKOVÁ V et al.: Clinical correlations of potential activity markers in systemic sclerosis. Ann N Y Acad Sci 2005; 1051: 404-12.
-
(2005)
Ann N Y Acad Sci
, vol.1051
, pp. 404-412
-
-
Becvár, R.1
Stork, J.2
Pesáková, V.3
-
136
-
-
0034856397
-
Serum levels of interleukin-6 and interleukin- 10 correlate with total skin thickness score in patients with systemic sclerosis
-
SATO S, HASEGAWA M, TAKEHARA K: Serum levels of interleukin-6 and interleukin- 10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001; 27: 140-6.
-
(2001)
J Dermatol Sci
, vol.27
, pp. 140-146
-
-
Sato, S.1
Hasegawa, M.2
Takehara, K.3
-
137
-
-
0030803853
-
Serum levels of soluble IL-2 receptor, soluble ICAM-1, TNF-alpha, interleukin-4 and interleukin-6 in scleroderma
-
BRUNS M, HAUSTEIN UF, HOFMANN C, HERRMANN K: Serum levels of soluble IL-2 receptor, soluble ICAM-1, TNF-alpha, interleukin-4 and interleukin-6 in scleroderma. J Eur Acad Dermatol Venereol 1997; 8: 222-8.
-
(1997)
J Eur Acad Dermatol Venereol
, vol.8
, pp. 222-228
-
-
Bruns, M.1
Haustein, U.F.2
Hofmann, C.3
Herrmann, K.4
-
138
-
-
0026601232
-
Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma
-
NEEDLEMAN BW, WIGLEY FM, STAIR RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35: 67-72.
-
(1992)
Arthritis Rheum
, vol.35
, pp. 67-72
-
-
Needleman, B.W.1
Wigley, F.M.2
Stair, R.W.3
-
139
-
-
42449111699
-
A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: Coronary artery calcification in cases and controls
-
KHURMA V, MEYER C, PARK GS et al.: A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: Coronary artery calcification in cases and controls. Arthritis Rheum 2008; 59: 591-7.
-
(2008)
Arthritis Rheum
, vol.59
, pp. 591-597
-
-
Khurma, V.1
Meyer, C.2
Park, G.S.3
-
140
-
-
42649146185
-
Cytokine concentrations in exhaled breath condensates in systemic sclerosis
-
EDMÉ JL, TELLART AS, LAUNAY D et al.: Cytokine concentrations in exhaled breath condensates in systemic sclerosis. Inflammation Res 2008; 57: 151-6.
-
(2008)
Inflammation Res
, vol.57
, pp. 151-156
-
-
Edmé, J.L.1
Tellart, A.S.2
Launay, D.3
-
141
-
-
0027717313
-
In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis, their role in early and late disease
-
KOCH AE, KRONFELD-HARRINGTON LB, SZEKANECZ Z et al.: In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis, their role in early and late disease. Pathobiology 1993; 61: 239-46.
-
(1993)
Pathobiology
, vol.61
, pp. 239-246
-
-
Koch, A.E.1
Kronfeld-Harrington, L.B.2
Szekanecz, Z.3
-
142
-
-
84883176445
-
Oxidative stress in Mexicans with diffuse cutaneous systemic sclerosis
-
March 2
-
CRUZ-DOMÍNGUEZ MP, MONTES-CORTES. DH, OLIVARES-CORICHI IM, VERA-LASTRA O, MEDINA G, JARA LJ: Oxidative stress in Mexicans with diffuse cutaneous systemic sclerosis. Rheumatol Int 2013 March 2
-
(2013)
Rheumatol Int
-
-
Cruz-DomíNguez, M.P.1
Montes-Cortes, D.H.2
Olivares-Corichi, I.M.3
Vera-Lastra, O.4
Medina, G.5
Jara, L.J.6
-
143
-
-
84871306916
-
Magnetic resonance imaging findings in patients with systemic scleroderma and musculoskeletal symptoms
-
SCHANZ S, HENES J, ULMER A et al.: Magnetic resonance imaging findings in patients with systemic scleroderma and musculoskeletal symptoms. Eur Radiol 2013; 23: 212-21.
-
(2013)
Eur Radiol
, vol.23
, pp. 212-221
-
-
Schanz, S.1
Henes, J.2
Ulmer, A.3
-
144
-
-
2442588462
-
Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation
-
LIS AD, BRZEZINSKA-WCISLO LA: Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation. Wiad Lek 2003; 56: 532-6.
-
(2003)
Wiad Lek
, vol.56
, pp. 532-536
-
-
Lis, A.D.1
Brzezinska-Wcislo, L.A.2
-
145
-
-
0028218523
-
IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis
-
SUZUKI H, TAKEMURA H, YOSHIZAKI K et al.: IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis. J Immunol 1994; 152: 935-42.
-
(1994)
J Immunol
, vol.152
, pp. 935-942
-
-
Suzuki, H.1
Takemura, H.2
Yoshizaki, K.3
-
146
-
-
0026690770
-
Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis
-
TAKEMURA H, SUZUKI H, YOSHIZAKI K et al.: Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum 1992; 35: 940-3.
-
(1992)
Arthritis Rheum
, vol.35
, pp. 940-943
-
-
Takemura, H.1
Suzuki, H.2
Yoshizaki, K.3
-
147
-
-
26244465904
-
Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis
-
De SANTIS M, BOSELLO S, La TORRE G et al.: Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005; 6: 96.
-
(2005)
Respir Res
, vol.6
, pp. 96
-
-
De Santis, M.1
Bosello, S.2
La Torre, G.3
-
148
-
-
77957914450
-
Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury
-
PENDERGRASS SA, HAYES E, FARINA G et al.: Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 2010; 5: e12106.
-
(2010)
PLoS One
, vol.5
-
-
Pendergrass, S.A.1
Hayes, E.2
Farina, G.3
-
149
-
-
0037282897
-
Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis
-
JINNIN M, IHN H, YAMANE K, ASANO Y, YAZAWA N, TAMAKI K: Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: 91-4.
-
(2003)
Clin Exp Rheumatol
, vol.21
, pp. 91-94
-
-
Jinnin, M.1
Ihn, H.2
Yamane, K.3
Asano, Y.4
Yazawa, N.5
Tamaki, K.6
-
150
-
-
0035038490
-
Renal vascular damage in Japanese patients with systemic sclerosis
-
NISHIJIMA C, SATO S, HASEGAWA M et al.: Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology 2001; 40: 406-9.
-
(2001)
Rheumatology
, vol.40
, pp. 406-409
-
-
Nishijima, C.1
Sato, S.2
Hasegawa, M.3
-
151
-
-
27544463468
-
Anti-DNA topoisomerase II a autoantibodies in Japanese patients with systemic sclerosis
-
HAYAKAWA I, HASEGAWA M, TAKEHARA K, SATO S: Anti-DNA topoisomerase II a autoantibodies in Japanese patients with systemic sclerosis. Arch Dermatol Res 2005; 297: 180-3.
-
(2005)
Arch Dermatol Res
, vol.297
, pp. 180-183
-
-
Hayakawa, I.1
Hasegawa, M.2
Takehara, K.3
Sato, S.4
-
152
-
-
22844452819
-
Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis
-
HAYAKAWA I, HASEGAWA M, MATSUSHITA T et al.: Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology 2005; 44: 873-8.
-
(2005)
Rheumatology
, vol.44
, pp. 873-878
-
-
Hayakawa, I.1
Hasegawa, M.2
Matsushita, T.3
-
153
-
-
8344262301
-
Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis
-
MIMURA Y, IHN H, JINNIN M et al.: Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis. Br J Dermatol 2004; 151: 803-8.
-
(2004)
Br J Dermatol
, vol.151
, pp. 803-808
-
-
Mimura, Y.1
Ihn, H.2
Jinnin, M.3
-
154
-
-
3042525240
-
Serum matrix metalloproteinase- 3 in systemic sclerosis
-
JINNIN M, IHN H, ASANO Y, YAMANE K, YAZAWA N, TAMAKI K: Serum matrix metalloproteinase- 3 in systemic sclerosis. Arch Dermatol Res 2004; 296: 25-9.
-
(2004)
Arch Dermatol Res
, vol.296
, pp. 25-29
-
-
Jinnin, M.1
Ihn, H.2
Asano, Y.3
Yamane, K.4
Yazawa, N.5
Tamaki, K.6
-
155
-
-
0025459492
-
Anticardiolipin antibodies and other immunological disorders in patients with systemic scleroderma
-
SPERANSKII AI, RIAZANTSEVA TA, GUSEVA NG, MELKUMOVA KL, IVANOVA SM: Anticardiolipin antibodies and other immunological disorders in patients with systemic scleroderma. Revmatologiia (Mosk) 1990; 3: 11-4.
-
(1990)
Revmatologiia (Mosk)
, vol.3
, pp. 11-14
-
-
Speranskii, A.I.1
Riazantseva, T.A.2
Guseva, N.G.3
Melkumova, K.L.4
Ivanova, S.M.5
-
156
-
-
84875860763
-
Low Socioeconomic Status (Measured by Education) and Outcomes in Systemic Sclerosis: Data from the Canadian Scleroderma Research Group
-
MANSOUR S, BONNER A, MUANGCHAN C, HUDSON M, BARON M, POPE JE; and The Canadian Scleroderma Research Group: Low Socioeconomic Status (Measured by Education) and Outcomes in Systemic Sclerosis: Data from the Canadian Scleroderma Research Group. J Rheumatol 2013; 40: 447-54.
-
(2013)
J Rheumatol
, vol.40
, pp. 447-454
-
-
Mansour, S.1
Bonner, A.2
Muangchan, C.3
Hudson, M.4
Baron, M.5
Pope, J.E.6
-
157
-
-
0030904129
-
Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis
-
BOLSTER MB, LUDWICKA A, SUTHERLAND SE, STRANGE C, SILVER RM: Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997; 40: 743-51.
-
(1997)
Arthritis Rheum
, vol.40
, pp. 743-751
-
-
Bolster, M.B.1
Ludwicka, A.2
Sutherland, S.E.3
Strange, C.4
Silver, R.M.5
-
158
-
-
0033677566
-
Clinical and laboratory features of scleroderma patients with pulmonary hypertension
-
YAMANE K, IHN H, ASANO Y et al.: Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology 2000; 39: 1269-71.
-
(2000)
Rheumatology
, vol.39
, pp. 1269-1271
-
-
Yamane, K.1
Ihn, H.2
Asano, Y.3
-
159
-
-
79955555100
-
Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition
-
MOK MY, LAU CS, CHIU SSH et al.: Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis Rheum 2011; 63: 1387-95.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 1387-1395
-
-
Mok, M.Y.1
Lau, C.S.2
Chiu, S.S.H.3
-
160
-
-
83555165261
-
Arthritis in patients with systemic sclerosis
-
SCHMEISER T, PONS-KüHNEMANN J, öZDEN F, MüLLER-LADNER U, DINSER R: Arthritis in patients with systemic sclerosis. Eur J Intern Med 2012; 23: e25-9.
-
(2012)
Eur J Intern Med
, vol.23
-
-
Schmeiser, T.1
Pons-Kühnemann, J.2
Özden, F.3
Müller-Ladner, U.4
Dinser, R.5
-
161
-
-
7244232680
-
Autoantibodies against phosphatidylserineprothrombin complex in patients with systemic sclerosis
-
HASEGAWA M, SATO S, YANABA K, KOMURA K, YAMAZAKI M, TAKEHARA K: Autoantibodies against phosphatidylserineprothrombin complex in patients with systemic sclerosis. Ann Rheum Dis 2004; 63: 1514-7.
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 1514-1517
-
-
Hasegawa, M.1
Sato, S.2
Yanaba, K.3
Komura, K.4
Yamazaki, M.5
Takehara, K.6
-
162
-
-
78651110762
-
Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: Possible association with myositis?
-
BASSYOUNI IH, AZAB NA, El-DAKRONY EHM, FAWZI MMT, GHANOUM R, BASSYOUNI RH: Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: Possible association with myositis?. Joint Bone Spine 2011; 78: 56-61.
-
(2011)
Joint Bone Spine
, vol.78
, pp. 56-61
-
-
Bassyouni, I.H.1
Azab, N.A.2
El-Dakrony, E.H.M.3
Fawzi, M.M.T.4
Ghanoum, R.5
Bassyouni, R.H.6
-
163
-
-
59149085881
-
Autoantibody against a protease domain of caspase-8 in patients with systemic sclerosis
-
YAMAOKA T, OGAWA F, MUROI E et al.: Autoantibody against a protease domain of caspase-8 in patients with systemic sclerosis. Clin Exp Rheumatol 2008; 26: 998-1004.
-
(2008)
Clin Exp Rheumatol
, vol.26
, pp. 998-1004
-
-
Yamaoka, T.1
Ogawa, F.2
Muroi, E.3
-
164
-
-
25444471513
-
Clinical correlations of potential activity markers in systemic sclerosis
-
BECVÁR R, STORK J, PESÁKOVÁ V et al.: Clinical correlations of potential activity markers in systemic sclerosis. Ann N Y Acad Sci 2005; 1051: 404-12.
-
(2005)
Ann N Y Acad Sci
, vol.1051
, pp. 404-412
-
-
Becvár, R.1
Stork, J.2
Pesáková, V.3
-
165
-
-
42249103262
-
Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with antitopoisomerase I antibodies and those with anticentromere antibody
-
KOMURA K, YANABA K, OGAWA F, SHIMIZU K, TAKEHARA K, SATO S: Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with antitopoisomerase I antibodies and those with anticentromere antibody. Clin Exp Dermatol 2008; 33: 329-32.
-
(2008)
Clin Exp Dermatol
, vol.33
, pp. 329-332
-
-
Komura, K.1
Yanaba, K.2
Ogawa, F.3
Shimizu, K.4
Takehara, K.5
Sato, S.6
-
166
-
-
84875861264
-
Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis
-
De LAURETIS A, SESTINI P, PANTELIDIS P et al.: Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis. J Rheumatol 2013; 40: 435-46.
-
(2013)
J Rheumatol
, vol.40
, pp. 435-446
-
-
De Lauretis, A.1
Sestini, P.2
Pantelidis, P.3
-
167
-
-
84859217173
-
Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis
-
TOMCíK M, ARIMA K, HULEJOVÁ H et al.: Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. Cytokine 2012; 58: 165-8.
-
(2012)
Cytokine
, vol.58
, pp. 165-168
-
-
Tomcík, M.1
Arima, K.2
Hulejová, H.3
-
168
-
-
0027503082
-
Cell surface expression of lysosome-associated membrane proteins (LAMPs) in scleroderma: relationship of lamp2 to disease duration, anti-Sc170 antibodies, serum interleukin-8, and soluble interleukin-2 receptor levels
-
HOLCOMBE RF, BAETHGE BA, STEWART RM et al.: Cell surface expression of lysosome-associated membrane proteins (LAMPs) in scleroderma: relationship of lamp2 to disease duration, anti-Sc170 antibodies, serum interleukin-8, and soluble interleukin-2 receptor levels. Clin Immunol Immunopathol 1993; 67: 31-9.
-
(1993)
Clin Immunol Immunopathol
, vol.67
, pp. 31-39
-
-
Holcombe, R.F.1
Baethge, B.A.2
Stewart, R.M.3
-
169
-
-
77953484773
-
Construct validity evaluation of the European scleroderma study group activity index, and investigation of possible new disease activity markers in systemic sclerosis
-
MINIER T, NAGY Z, BÁLINT Z et al.: Construct validity evaluation of the European scleroderma study group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology 2010; 49: 1133-45.
-
(2010)
Rheumatology
, vol.49
, pp. 1133-1145
-
-
Minier, T.1
Nagy, Z.2
Bálint, Z.3
-
170
-
-
67650523691
-
Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis
-
SCHOINDRE Y, MEUNE C, DINH-XUAN AT, AVOUAC J, KAHAN A, ALLANORE Y: Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol 2009; 36: 1481-5.
-
(2009)
J Rheumatol
, vol.36
, pp. 1481-1485
-
-
Schoindre, Y.1
Meune, C.2
Dinh-Xuan, A.T.3
Avouac, J.4
Kahan, A.5
Allanore, Y.6
-
171
-
-
0031056613
-
Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis
-
HASEGAWA M, FUJIMOTO M, KIKUCHI K, TAKEHARA K: Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997; 24: 328-32.
-
(1997)
J Rheumatol
, vol.24
, pp. 328-332
-
-
Hasegawa, M.1
Fujimoto, M.2
Kikuchi, K.3
Takehara, K.4
-
172
-
-
1542410396
-
Elevated circulating CD40L concentrations in patients with systemic sclerosis
-
KOMURA K, SATO S, HASEGAWA M, FUJIMOTO M, TAKEHARA K: Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 2004; 31: 514-9.
-
(2004)
J Rheumatol
, vol.31
, pp. 514-519
-
-
Komura, K.1
Sato, S.2
Hasegawa, M.3
Fujimoto, M.4
Takehara, K.5
-
173
-
-
51849160858
-
The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis
-
GUIDUCCI S, DISTLER JHW, JüNGEL A et al.: The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 2845-53.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 2845-2853
-
-
Guiducci, S.1
Distler, J.H.W.2
Jüngel, A.3
-
174
-
-
77649334839
-
Blood serum levels of amino-terminal pro-c-type natriuretic peptide in patients with systemic sclerosis
-
OLEWICZ-GAWLIK A, DANCZAK-PAZDROW-SKA A, KLAMA K et al.: Blood serum levels of amino-terminal pro-c-type natriuretic peptide in patients with systemic sclerosis. Connect Tissue Res 2010; 51: 83-7.
-
(2010)
Connect Tissue Res
, vol.51
, pp. 83-87
-
-
Olewicz-Gawlik, A.1
Danczak-Pazdrow-Ska, A.2
Klama, K.3
-
175
-
-
84856022022
-
Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-a treatment
-
HAPPONEN KE, SAXNE T, GEBOREK P et al.: Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-a treatment. Arthritis Res Ther 2012; 14: R15.
-
(2012)
Arthritis Res Ther
, vol.14
-
-
Happonen, K.E.1
Saxne, T.2
Geborek, P.3
-
176
-
-
12244264813
-
Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis
-
ALLANORE Y, BORDERIE D, LEMARÉCHAL H, CHERRUAU B, EKINDJIAN OG, KAHAN A: Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 2003; 30: 68-73.
-
(2003)
J Rheumatol
, vol.30
, pp. 68-73
-
-
Allanore, Y.1
Borderie, D.2
Lemaréchal, H.3
Cherruau, B.4
Ekindjian, O.G.5
Kahan, A.6
-
177
-
-
79959580692
-
Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis
-
OGAWA F, SHIMIZU K, MUROI E, HARA T, SATO S: Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis. Clin Rheumatol 2011; 30: 921-5.
-
(2011)
Clin Rheumatol
, vol.30
, pp. 921-925
-
-
Ogawa, F.1
Shimizu, K.2
Muroi, E.3
Hara, T.4
Sato, S.5
-
178
-
-
52649135593
-
Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: Association with fibrosis vascular damage
-
OGAWA F, SHIMIZU K, HARA T et al.: Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: Association with fibrosis vascular damage. Clin Exp Rheumatol 2008; 26: 659-62.
-
(2008)
Clin Exp Rheumatol
, vol.26
, pp. 659-662
-
-
Ogawa, F.1
Shimizu, K.2
Hara, T.3
-
179
-
-
84885181545
-
Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis
-
Sep 13 [Epub ahead of print]
-
TAKAHASHI T, ASANO Y, AKAMATA K et al.: Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis. Mod Rheumatol 2012 Sep 13 [Epub ahead of print].
-
(2012)
Mod Rheumatol
-
-
Takahashi, T.1
Asano, Y.2
Akamata, K.3
-
180
-
-
77956485173
-
Is serum albumin a marker of malnutrition in chronic disease? the scleroderma paradigm
-
BARON M, HUDSON M, STEELE R et al.: Is serum albumin a marker of malnutrition in chronic disease? the scleroderma paradigm. J Am Coll Nutr 2010; 29: 144-51.
-
(2010)
J Am Coll Nutr
, vol.29
, pp. 144-151
-
-
Baron, M.1
Hudson, M.2
Steele, R.3
-
181
-
-
78649326513
-
Very low levels of vitamin D in systemic sclerosis patients
-
CARAMASCHI P, DALLA GASSA A, RUZZENENTE O et al.: Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 2010; 29: 1419-25.
-
(2010)
Clin Rheumatol
, vol.29
, pp. 1419-1425
-
-
Caramaschi, P.1
Dalla Gassa, A.2
Ruzzenente, O.3
-
182
-
-
57049160458
-
Haemorheological profile in patients with systemic sclerosis
-
VAYÁ A, TODOLí J, CALVO J, ROMAGNOLI M, RICART JM: Haemorheological profile in patients with systemic sclerosis. Clin Hemorheol Microcirc 2008; 40: 243-8.
-
(2008)
Clin Hemorheol Microcirc
, vol.40
, pp. 243-248
-
-
Vayá, A.1
Todolí, J.2
Calvo, J.3
Romagnoli, M.4
Ricart, J.M.5
-
183
-
-
84865176917
-
Aldolase predicts subsequent myopathy occurrence in systemic sclerosis
-
TOLÉDANO C, GAIN M, KETTANEH A et al.: Aldolase predicts subsequent myopathy occurrence in systemic sclerosis. Arthritis Res Ther 2012; 14: R152.
-
(2012)
Arthritis Res Ther
, vol.14
-
-
Tolédano, C.1
Gain, M.2
Kettaneh, A.3
-
184
-
-
2342652959
-
Clinical determinants of bone mass and bone ultrasonometry in patients with systemic sclerosis
-
FREDIANI B, BALDI F, FALSETTI P et al.: Clinical determinants of bone mass and bone ultrasonometry in patients with systemic sclerosis. Clin Exp Rheumatol 2004; 22: 313-8.
-
(2004)
Clin Exp Rheumatol
, vol.22
, pp. 313-318
-
-
Frediani, B.1
Baldi, F.2
Falsetti, P.3
-
185
-
-
14044254256
-
Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement
-
MOYSSAKIS I, GIALAFOS E, VASSILIOU V et al.: Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement. Rheumatology 2005; 44: 251-4.
-
(2005)
Rheumatology
, vol.44
, pp. 251-254
-
-
Moyssakis, I.1
Gialafos, E.2
Vassiliou, V.3
-
186
-
-
67449100026
-
Increased serum pentraxin 3 in patients with systemic sclerosis
-
IWATA Y, YOSHIZAKI A, OGAWA F et al.: Increased serum pentraxin 3 in patients with systemic sclerosis. J Rheumatol 2009; 36: 976-83.
-
(2009)
J Rheumatol
, vol.36
, pp. 976-983
-
-
Iwata, Y.1
Yoshizaki, A.2
Ogawa, F.3
-
187
-
-
34447536609
-
Normal circulating serum amyloid P component concentration in systemic sclerosis
-
TENNENT GA, DZIADZIO M, TRIANTAFILLIDOU E et al.: Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis Rheum 2007; 56: 2013-7.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 2013-2017
-
-
Tennent, G.A.1
Dziadzio, M.2
Triantafillidou, E.3
-
188
-
-
1842607206
-
Bioactivity of prolactin in systemic sclerosis
-
La MONTAGNA G, MELI R, CRISCUOLO T, D'ANGELO S, VALENTINI G: Bioactivity of prolactin in systemic sclerosis. Clin Exp Rheumatol 2004; 22: 145-50.
-
(2004)
Clin Exp Rheumatol
, vol.22
, pp. 145-150
-
-
La Montagna, G.1
Meli, R.2
Criscuolo, T.3
D'angelo, S.4
Valentini, G.5
-
190
-
-
60149109220
-
Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing
-
ALIVERNINI S, De SANTIS M, TOLUSSO B et al.: Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing. J Am Acad Dermatol 2009; 60: 426-35.
-
(2009)
J Am Acad Dermatol
, vol.60
, pp. 426-435
-
-
Alivernini, S.1
De Santis, M.2
Tolusso, B.3
-
191
-
-
84883764649
-
Nailfold capillaroscopy abnormalities as predictors of mortality in patients with systemic sclerosis
-
KAYSER C, SEKIYAMA JY, PRóSPERO LC, CAMARGO CZ, ANDRADE LE: Nailfold capillaroscopy abnormalities as predictors of mortality in patients with systemic sclerosis. Clin Exp Rheumatol 2013; 31 (Suppl. 76): S115-S117.
-
(2013)
Clin Exp Rheumatol
, vol.31
, Issue.SUPPL. 76
-
-
Kayser, C.1
Sekiyama, J.Y.2
Próspero, L.C.3
Camargo, C.Z.4
Andrade, L.E.5
-
192
-
-
0030897920
-
Von willebrand factor: Increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies
-
BLANN AD, SHEERAN TP, EMERY P: Von willebrand factor: Increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies. Br J Biomed Sci 1997; 54: 5-9.
-
(1997)
Br J Biomed Sci
, vol.54
, pp. 5-9
-
-
Blann, A.D.1
Sheeran, T.P.2
Emery, P.3
-
193
-
-
78049421175
-
The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
-
SHIMA Y, KUWAHARA Y, MUROTA H et al.: The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010; 49: 2408-12.
-
(2010)
Rheumatology
, vol.49
, pp. 2408-2412
-
-
Shima, Y.1
Kuwahara, Y.2
Murota, H.3
-
194
-
-
84923345569
-
Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab
-
March 1 [Epub ahead of print]
-
SHIMA Y, HOSEN N, HIRANO T et al.: Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Mod Rheumatol 2013 March 1 [Epub ahead of print].
-
(2013)
Mod Rheumatol
-
-
Shima, Y.1
Hosen, N.2
Hirano, T.3
-
195
-
-
77956992383
-
B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial
-
BOSELLO S, De SANTIS M, LAMA G et al.: B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12: R54.
-
(2010)
Arthritis Res Ther
, vol.12
-
-
Bosello, S.1
De Santis, M.2
Lama, G.3
-
196
-
-
79957789715
-
Evaluation of the effect of bosentan treatment on proinflammatory cytokine serum levels in patients affected by systemic sclerosis
-
BELLISAI F, MOROZZI G, SCACCIA F et al.: Evaluation of the effect of bosentan treatment on proinflammatory cytokine serum levels in patients affected by systemic sclerosis. Int J Immunopathol Pharmacol 2011; 24: 261-4.
-
(2011)
Int J Immunopathol Pharmacol
, vol.24
, pp. 261-264
-
-
Bellisai, F.1
Morozzi, G.2
Scaccia, F.3
-
197
-
-
35748954048
-
Statins as immunomodulators in systemic sclerosis
-
ABOU-RAYA A, ABOU-RAYA S, HELMII M: Statins as immunomodulators in systemic sclerosis. Ann N Y Acad Sci 2007; 1110: 670-80.
-
(2007)
Ann N Y Acad Sci
, vol.1110
, pp. 670-680
-
-
Abou-Raya, A.1
Abou-Raya, S.2
Helmii, M.3
-
198
-
-
47349091867
-
Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis
-
Del PAPA N, CORTIANA M, VITALI C et al.: Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol 2008; 35: 1323-8.
-
(2008)
J Rheumatol
, vol.35
, pp. 1323-1328
-
-
Del Papa, N.1
Cortiana, M.2
Vitali, C.3
-
199
-
-
79960969618
-
Pleiotropic effects of statins in systemic sclerosis
-
ALEKPEROV RT, KORZENEVA EG, ALEKSANDROVA EN, NOVIKOV AA, ANAN'EVA LP: Pleiotropic effects of statins in systemic sclerosis. Ter Arkh 2011; 83: 41-7.
-
(2011)
Ter Arkh
, vol.83
, pp. 41-47
-
-
Alekperov, R.T.1
Korzeneva, E.G.2
Aleksandrova, E.N.3
Novikov, A.A.4
Anan'Eva, L.P.5
-
200
-
-
0028211614
-
Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide
-
ÅKESSON A, SCHEJA A, LUNDIN A, WOLLHEIM FA: Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37: 729-35.
-
(1994)
Arthritis Rheum
, vol.37
, pp. 729-735
-
-
Åkesson, A.1
Scheja, A.2
Lundin, A.3
Wollheim, F.A.4
-
201
-
-
67651173119
-
Cyclophosphamide: Effective in the treatment of severe cutaneous involvement in systemic sclerosis
-
de MACEDO PA, BORGES CTL, de SOUZA RBC: Cyclophosphamide: Effective in the treatment of severe cutaneous involvement in systemic sclerosis. Revista Brasileira de Reumatologia 2009; 49: 270-5.
-
(2009)
Revista Brasileira de Reumatologia
, vol.49
, pp. 270-275
-
-
de Macedo, P.A.1
Borges, C.T.L.2
de Souza, R.B.C.3
-
202
-
-
84883806077
-
Prolonged treatment with transcutaneous electrical nerve stimulation (TENS) modulates neuro-gastric motility and plasma levels of vasoactive intestinal peptide (VIP), motilin and interleukin-6 (IL-6) in systemic sclerosis
-
McNEARNEY TA, SALLAM HS, HUNNICUTT SE, DOSHI D, CHEN JD: Prolonged treatment with transcutaneous electrical nerve stimulation (TENS) modulates neuro-gastric motility and plasma levels of vasoactive intestinal peptide (VIP), motilin and interleukin-6 (IL-6) in systemic sclerosis. Clin Exp Rheumatol 2013; 31 (Suppl. 76): S140-S150.
-
(2013)
Clin Exp Rheumatol
, vol.31
, Issue.SUPPL. 76
-
-
McNearney, T.A.1
Sallam, H.S.2
Hunnicutt, S.E.3
Doshi, D.4
Chen, J.D.5
|